Updated Jul 16, 2026
Khindri Sanjeev has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $355K.

Sanjeev Khindri is identified as the Chief Development Officer (CDO) at Liquidia Corp in the SEC filing dated January 21, 2026 (CIK 0002104932). Liquidia is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension and related conditions, leveraging its PRINT technology platform. The filing notes his role within Liquidia, reflecting leadership over development-related activities at the company.
| Role | Chief Development Officer |
|---|---|
| Notability | 40/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 1.1K | $71.52 | $79K |
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 84 | $71.39 | $6K |
| 2026-06-10 | LQDA | Liquidia Corp | S — Open-market sale | 4.1K | $65.46 | $271K |
| 2026-01-21 | LQDA | Liquidia Corp | A — Grant or award | 34.3K | $0.00 |
Sanjeev Khindri is identified as the Chief Development Officer (CDO) at Liquidia Corp in the SEC filing dated January 21, 2026 (CIK 0002104932). Liquidia is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension and related conditions, leveraging its PRINT technology platform. The filing notes his role within Liquidia, reflect…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($355K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Khindri Sanjeev profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.